West Pharmaceutical Services (NYSE:WST) Hits New 52-Week High – Should You Buy?

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) reached a new 52-week high on Wednesday . The company traded as high as $345.28 and last traded at $345.3490, with a volume of 19890 shares trading hands. The stock had previously closed at $336.39.

Analyst Upgrades and Downgrades

WST has been the subject of a number of recent analyst reports. Morgan Stanley boosted their price objective on West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a report on Friday, May 29th. Evercore reissued an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Wolfe Research started coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target on the stock. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $340.09.

West Pharmaceutical Services Stock Up 2.6%

The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07. The firm has a market cap of $24.38 billion, a PE ratio of 46.17, a P/E/G ratio of 2.76 and a beta of 1.18. The business’s 50-day simple moving average is $308.92 and its 200 day simple moving average is $274.16.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.45. The firm had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, equities research analysts expect that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Elyxium Wealth LLC acquired a new stake in West Pharmaceutical Services in the fourth quarter valued at approximately $25,000. Bayban acquired a new position in shares of West Pharmaceutical Services during the fourth quarter worth $27,000. Private Trust Co. NA lifted its holdings in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 61 shares during the last quarter. DV Equities LLC acquired a new stake in shares of West Pharmaceutical Services in the 4th quarter worth $28,000. Finally, Cornerstone Planning Group LLC grew its stake in West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 50 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.